Portfolio News
- February 26, 2013 Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia
- February 25, 2013 Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI
- February 04, 2013 - BioWorld TodayBulls Proved Right: Hyperion's Ravicti Wins Approval in UCD
- January 31, 2013 KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
- January 31, 2013 Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication
- January 25, 2013 KaloBios on path toward $50 million IPO
- January 22, 2013 Cortina's New 15G CDR and Backplane PHY Leads Industry in Performance, Density and Low Power
- January 17, 2013 Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Spain For The Treatment Of Chronic Diabetic Macular Edema
- January 10, 2013 Guavus raises $30 million for data analytics
- January 08, 2013 CrestaTech Announces 4th Generation Smart Tuner; TheX7 for Flat Panel TVs
- January 07, 2013 CrestaTech Enhances Management, Prepares to Launch Variety of Smart Tuner Products in New Year
- January 03, 2013 Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer
- December 04, 2012 Salveo Specialty Pharmacy, Inc.Completes Additional Equity and Debt Financings and Acquisition of Mission Road Pharmacy
- November 26, 2012 Amarin Announces Notification of Patent Allowance for U.S. Application 13/610,247 Related to Vascepa(R) and FDA Approved MARINE Indication
- October 24, 2012 Mirna Therapeutics Secures $34.5 Million Series C Financing to Advance Oncology microRNA Pipeline into the Clinic